ST. DAVID'S, BERMUDA - Warner Chilcott Limited announced in a Tuesday press release that its subsidiary Warner Chilcott Company Inc. and Barr Laboratories Inc., a subsidiary of Barr Pharmaceuticals Inc., have entered into a Settlement and License Agreement to resolve the pending patent litigation involving Warner Chilcott's oral contraceptive product, Femcon Fe.
Under the terms of the agreement, Barr will have a license to launch a generic version of Femcon Fe as early as July 1, 2012, approximately seven years earlier than the expiration of the Warner Chilcott patent at issue in the litigation, or earlier in certain circumstances.
Barr will pay Warner Chilcott a royalty on net sales of Barr's generic product. The parties will promptly file a dismissal without prejudice in the United States District Court for the District of New Jersey that will conclude this litigation.
Warner Chilcott is a specialty pharmaceutical company focused on developing, manufacturing, marketing and selling branded prescription pharmaceutical products in women's healthcare and dermatology in the US.
Barr Pharmaceuticals Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients.
From:www.ag-ip-news.com
